Treatment of adult ADHD: Is current knowledge useful to clinicians?

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 B, 2008, Pages 177-186

  Torgersen, Terje ^a,b   Gjervan, Bjørn ^a,c   Rasmussen, Kirsten ^c  

^a Levanger Hospital   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

ADHD; Adults; Comorbidity; Psychotherapy; Stimulants; Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; PLACEBO;

ADULT; ALCOHOL ABUSE; ANXIETY; ATTENTION DEFICIT DISORDER; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LONG TERM CARE; MOOD DISORDER; OUTCOME ASSESSMENT; PERSONALITY DISORDER; PSYCHOTHERAPY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; REVIEW; SUBSTANCE ABUSE;

EID: 41549163911     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1223     Document Type: Review

References (65)

1. Aanonsen NO, Lensing MB, Prietz R, et al. 2004. Utproevende behandling med sentralstimulerende legemidler til voksne med hyperkinetisk forstyrrelse/ADHD. Oslo: Ullevaal University Hospital.
2. Adler LA, Reingold LS, Morrill MS, et al. 2006. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep, 8:409-15.
3. Adler LA, Spencer TJ, Milton DR, et al. 2005. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry, 66:294-9.
4. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington: American Psychiatric Association.
5. Asherson P, Chen W, Craddock B, et al. 2007. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry, 190:4-5.
6. Barkley RA, Murphy KR, O'Connell T, et al. 2005. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. J Safety Res, 36:121-31.
7. Biederman J, Mick E, Surman C, et al. 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 59:829-35.
8. Biederman J, Spencer TJ, Wilens TE, et al. 2005. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr, 10:16-25.
9. Bouffard R, Hechtman L, Minde K, et al. 2003. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry, 48:546-54.
10. Capone N, McDonnel T. 2006. Medication persistence among agents used to treat attention-deficit/hyperactivity disorder, diabetes, and elevated serum cholesterol. In American Psychiatric Association 2006 Annual meeting. Toronto: American Psychiatric Association.
11. Carpentier PJ, de Jong CA, Dijkstra BA, et al. 2005. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction, 100:1868-74.
12. Clarke S, Heussler H, Kohn MR. 2005. Attention deficit disorder: not just for children. Intern Med J, 35:721-5.
13. Dodson WW. 2005. Pharmacotherapy of adult ADHD. J Clin Psychol, 61:589-606.
14. Faraone SV, Biederman J, Mick E. 2006. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med, 36:159-65.
15. Faraone SV, Spencer T, Aleardi M, et al. 2004. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol, 24:24-9.
16. Foreman DM, Foreman D, Prendergast M, et al. 2001. Is clinic prevalence of ICD-10 hyperkinesis underestimated? Impact of increasing awareness by a questionnaire screen in an UK clinic. Eur Child Adolesc Psychiatry, 10:130-4.
17. Gordon M, Antshel K, Faraone S, et al. 2006. Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J Atten Disor, 9:465-75.
18. Gualtieri CT, Ondrusek MG, Finley C. 1985. Attention deficit disorders in adults. Clin Neuropharmacol, 8:343-56.
19. Hesslinger B, van Tebartz EL, Nyberg E, et al. 2002. Psychotherapy of attention deficit hyperactivity disorder in adults - a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci, 252:177-84.
20. Jensen PS, Martin D, Cantwell DP. 1997. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry, 36:1065-79.
21. Kooij JJ, Buitelaar JK, van den Oord EJ, et al. 2005. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med, 35:817-27.
22. Kooij JJ, Burger H, Boonstra AM, et al. 2004. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med, 34:973-82.
23. Kuperman S, Perry PJ, Gaffney GR, et al. 2001. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry, 13:129-34.
24. Levin ED, Conners CK, Silva D, et al. 2001. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol, 9:83-90.
25. Levin FR, Evans SM, Brooks DJ, et al. 2007. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend, 87:20-9.
26. Levin FR, Evans SM, Brooks DJ, et al. 2006. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend, 81:137-48.
27. Mattes JA, Boswell L, Oliver H. 1984. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry, 41:1059-1063.
28. Michelson D, Adler L, Spencer T, et al. 2003. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry, 53:112-20.
29. MTA Cooperative Group. 2004. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics, 113:754-61.
30. Murphy K, Barkley RA. 1996. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry, 37:393-401.
31. Nutt DJ, Fone K, Asherson P, et al. 2007. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 21:10-41.
32. Paterson R, Douglas C, Hallmayer J, et al. 1999. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry, 33:494-502.
33. Perwien A, Hall J, Swensen A, et al. 2004. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm, 10: 122-9.
34. Rasmussen K, Almvik R, Levander S. 2001. Attention deficit hyperactivity disorder, reading disability, and personality disorders in a prison population. J Am Acad Psychiatry Law, 29:186-93.
35. Reimherr FW, Williams ED, Strong RE, et al. 2007. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry, 68:93-101.
36. Rostain AL, Ramsay JR. 2006. A combined treatment approach for adults with ADHD - results of an open study of 43 patients. J Atten Disord, 10:150-9.
37. Safren SA, Otto MW, Sprich S, et al. 2005. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther, 43:831-42.
38. Schachter HM, Pham B, King J, et al. 2001. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ, 165:1475-88.
39. Schubiner H, Saules KK, Arfken CL, et al. 2002. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol, 10:286-94.
40. Smith BH, Waschbusch DA, Willoughby MT, et al. 2000. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev, 3:243-67.
41. Spencer T, Biederman J, Wilens T, et al. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 57:456-63.
42. Spencer T, Biederman J, Wilens T, et al. 2001. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry, 58:775-82.
43. Spencer T, Biederman J, Wilens T, et al. 1998. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry, 155:693-5.
44. Spencer T, Wilens T, Biederman J, et al. 1995. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry, 52:434-43.
45. Spencer TJ, Adler LA, McGough JJ, et al. 2007. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry, 15:1380-7.
46. Stevenson CS, Stevenson RJ, Whitmont S. 2003. A self-directed psychosocial intervention with minimal therapist contact for adults with attention deficit hyperactivity disorder. Clin Psychol Psychother, 10:93-101.
47. Stevenson CS, Whitmont S, Bornholt L, et al. 2002. A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. Aust N J Psychiatry, 36:610-6.
48. Taylor, FB, Russo J. 2000. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol, 10:311-20.
49. Taylor FB, Russo J. 2001. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol, 21:223-8.
50. Tenenbaum S, Paull JC, Sparrow EP, et al. 2002. An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). J Atten Disord, 6:49-60.
51. Torgersen T, Gjervan B, Rasmussen K. 2006. ADHD in adults: a study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry, 60:38-43.
52. Tripp G, Luk SL, Schaughency EA, et al. 1999. DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. J Am Acad Child Adolesc Psychiatry, 38:156-64.
53. Walsh BT, Seidman SN, Sysko R, et al. 2002. Placebo response in studies of major depression: variable, substantial, and growing. JAMA, 287:1840-7.
54. Weisler RH, Biederman J, Spencer TJ, et al. 2006. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trialCNS Spectr, 11:625-39.
55. Weiss M, Hechtman L. 2006. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry, 67:611-9.
56. Weiss MD, Gadow K, Wasdell MB. 2006. Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry, 67:38-45.
57. Wender PH. 1998. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry, 59:76-9.
58. Wender PH, Reimherr FW, Wood D, et al. 1985. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry, 142:547-52.
59. Wilens TE, Biederman J, Prince J, et al. 1996. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry, 153:1147-53.
60. Wilens TE, Biederman J, Spencer TJ. 2002. Attention deficit/ hyperactivity disorder across the lifespan. Annu Rev Med, 53:113-31.
61. Wilens TE, Haight BR, Horrigan JP, et al. 2005. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry, 57:793-801.
62. Wilens TE, Spencer TJ, Biederman J. 2002. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord, 5:189-202.
63. Wilens TE, Spencer TJ, Biederman J, et al. 200 1. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry, 158:282-88.
64. Wood DR, Reimherr FW, Wender PH, et al. 1976. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry, 33:1453-60.
65. World Health Organization. 1992. The International Classification of Disease, 10th revision. Geneva: World Health Organization.